Adverse Events: Race, Inequality, and the Testing of New Pharmaceuticals Free Audiobook Download by Jill A. Fisher

In this audiobook, Fisher argues that it is often impossible to identify the root causes of why some people are more susceptible than others to certain adverse events. The pharmaceutical industry spends hundreds of billions of dollars annually on researching drugs and discovering new treatments for diseases, but only a small percentage make it past clinical trials. Only five of 10 drugs tested in clinical trails make it past the first phase before being rejected by the FDA, and less than two-thirds make it through the entire process. Fisher argues that the evidence suggests that these problems are not just random occurrences, but systemic ones.

This memoir by Jill A. Fisher narrates her life's journey to find the answers to questions concerning the testing of new pharmaceuticals, which focuses on race, inequality, and how these two factors affect one another.

In this book, Jill A. Fisher uses controlled experiments and personal narratives to show how the testing of new pharmaceuticals has led to greater health inequalities, and how that disparity has been caused by disparate treatment of people according to race and class.

Originally published in 2011, this audiobook was written as a review of the research conducted by Dr. Fisher and others on the subject of adverse events (AE) associated with new pharmaceuticals. Jill A. Fisher starts by discussing the move to test chemical mixtures and then moves on to discuss the risks of these chemical combinations, which are not always known upfront in some cases.

ADVERSE EVENTS tells the stories of the ones who bear the burdens of adverse drug reactions, and their struggles and triumphs in navigating their personal journeys. The book highlights the stories of those who experienced negative outcomes as a result of pharmaceutical testing, interviewing patients and doctors about what happened to them and how they were affected.

Jill Fisher talks about the remarkable increase in adverse events from new drugs, specifically from some who are tested on poor and minorities. Fisher also discusses how these events can be credited for bringing a spotlight on the drug industry.